Abstract
Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.
| Original language | English |
|---|---|
| Article number | 54 |
| Journal | BMC Ophthalmology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2015 May 28 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Ophthalmology
Cite this
}
Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma. / Hong, Samin; Han, Sueng Han; Kim, Chan Yun; Kim, Kang Yoon; Song, Yoo Kyung; Seong, Gong Je.
In: BMC Ophthalmology, Vol. 15, No. 1, 54, 28.05.2015.Research output: Contribution to journal › Article
TY - JOUR
T1 - Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon's fibroblasts Glaucoma
AU - Hong, Samin
AU - Han, Sueng Han
AU - Kim, Chan Yun
AU - Kim, Kang Yoon
AU - Song, Yoo Kyung
AU - Seong, Gong Je
PY - 2015/5/28
Y1 - 2015/5/28
N2 - Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.
AB - Background: Brimonidine is a highly selective α2 adrenergic agonist that has been widely used in anti-glaucoma eyedrops. The aim of this study was to investigate its putative anti-fibrotic role in the fibrosis caused by activated Tenon's fibroblasts. Methods: Primary cultured human Tenon's fibroblasts were exposed to 2.0 ng/mL of transforming growth factor-β1 (TGF-β1) for up to 48 h. In the presence of various concentrations of brimonidine (from 0.0 to 10.0 μM), the expression levels of fibronectin, collagen types I and III, and β-actin were determined by Western immunoblots. The expression of phosphorylated SMAD2/3 (p-SMAD2/3) was then evaluated using immunofluorescence. Results: TGF-β1 significantly increased the synthesis of fibronectin and collagens in human Tenon's fibroblasts; however brimonidine treatment distinctly attenuated the TGF-β1-induced production of extracellular matrix (ECM) proteins. TGF-β1 also changed the cellular morphology to be plump, while brimonidine treatment returned the cells to a spindle shape, similar to control fibroblasts. Regarding p-SMAD2/3, brimonidine treatment did not show any apparent changes in its expression. Conclusions: Our data revealed that brimonidine reduces TGF-β-induced ECM synthesis in human Tenon's fibroblasts in vitro. This finding implies that topical administration of brimonidine may be helpful in reducing the fibrosis caused by the long-term use of topical anti-glaucoma medications.
UR - http://www.scopus.com/inward/record.url?scp=84934873349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934873349&partnerID=8YFLogxK
U2 - 10.1186/s12886-015-0045-8
DO - 10.1186/s12886-015-0045-8
M3 - Article
C2 - 26017119
AN - SCOPUS:84934873349
VL - 15
JO - BMC Ophthalmology
JF - BMC Ophthalmology
SN - 1471-2415
IS - 1
M1 - 54
ER -